{"title":"Chapter 4: ART for people living with HIV","nid":650,"vid":2918,"created":1636991493,"changed":1641456422,"field_accordian_header":[{"field_accordian":[{"field_title":"All populations","field_content":"<p>ART should be initiated for all people living with HIV regardless of WHO clinical stage and at any CD4 cell count.<\/p>\r\n\r\n<ul>\r\n\t<li>Adults <em>(strong recommendation, moderate-certainty evidence)<\/em><\/li>\r\n\t<li>Pregnant and breastfeeding women <em>(strong recommendation, moderate-certainty evidence)<\/em><\/li>\r\n\t<li>Adolescents <em>(conditional recommendation, low-certainty evidence)<\/em><\/li>\r\n\t<li>Children living with HIV one year old to less than 10 years old <em>(conditional recommendation, low-certainty evidence)<\/em><\/li>\r\n\t<li>Infants diagnosed in the first year of life <em>(strong recommendation, moderate-certainty evidence)<\/em><\/li>\r\n<\/ul>\r\n","field_icon":null}],"field_header":"4.4 When to start ART"},{"field_accordian":[{"field_title":"4.5.1 Rapid ART initiation","field_content":"<p>Rapid ART initiation\" should be offered to all people living with HIV following a confirmed HIV diagnosis and clinical assessment (strong recommendation: high-certainty evidence for adults and adolescents; low-certainty evidence for children).<\/p>\r\n\r\n<p>\u1d43 Rapid initiation is defined as within seven days from the day of HIV diagnosis; people with advanced HIV disease should be given priority for assessment and initiation.<\/p>\r\n\r\n<p>ART initiation should be offered on the same day to people who are ready to start <em>(strong recommendation: high-certainty evidence for adults and adolescents; low-certainty evidence for children).<\/em><\/p>\r\n\r\n<p><strong>Good practice statement<\/strong><\/p>\r\n\r\n<p>ART initiation should follow the overarching principles of providing people-centred care. People-centred care should be focused and organized around the health needs, preferences and expectations of people and communities, upholding individual dignity and respect, especially for vulnerable populations, and should promote engaging and supporting people and families to play an active role in their own care by informed decision-making. People should be encouraged but not coerced to start ART immediately and should be supported in making an informed choice regarding when to start ART and what ARV drug regimen to use.<\/p>\r\n","field_icon":null},{"field_title":"4.5.2 Timing of ART for adults, adolescents and children being treated for HIV-associated TB","field_content":"<p>ART should be started as soon as possible within two weeks of initiating TB treatment, regardless of CD4 cell count, among people living with HIV.a<\/p>\r\n\r\n<p>Adults and adolescents <em>(strong recommendation, low- to moderate-certainty evidence)<\/em><\/p>\r\n\r\n<p>Children and infants <em>(strong recommendation, very-low-certainty evidence)<\/em><\/p>\r\n\r\n<p>\u1d43 Except when signs and symptoms of meningitis are present.<\/p>\r\n","field_icon":null},{"field_title":"4.5.3 Timing of ART for people living with HIV and cryptococcal meningitis","field_content":"<p>Immediate ART initiation is not recommended for adults, adolescents and children living with HIV who have cryptococcal meningitis because of the risk of increased mortality and should be deferred by 4-6 weeks from the initiation of antifungal treatment <em>(strong recommendation, low-certainty evidence for adults and very-low-certainty evidence for children and adolescents).<\/em><\/p>\r\n","field_icon":null},{"field_title":"4.5.4 Timing of ART for people living with HIV and histoplasmosis","field_content":"<p>ART should be initiated as soon as possible among people with disseminated histoplasmosis for whom central nervous system involvement is not suspected or proven <em>(conditional recommendation, very-low-certainty evidence).<\/em><\/p>\r\n","field_icon":null}],"field_header":"4.5 Timing of ART"},{"field_accordian":[{"field_title":"4.6.1 First-line ART","field_content":"<p><strong>Preferred regimen<\/strong><\/p>\r\n\r\n<p>1. DTG in combination with an NRTI backbone is recommended as the preferred first-line regimen for people living with HIV initiating ART.\u1d43<\/p>\r\n\r\n<ul>\r\n\t<li>Adults and adolescents <em>(strong recommendation, moderate-certainty evidence)<\/em><\/li>\r\n\t<li>Infants and children with approved DTG dosing\u1d47 <em>(conditional recommendation, low-certainty evidence)<\/em><\/li>\r\n<\/ul>\r\n\r\n<p>\u1d43 In settings or populations in which DTG is not accessible or unsuitable because of toxicity and national levels of pretreatment HIV drug resistance are \u226510%, PI\/r-based ARV drugs should be used in first-line ART. The choice of PI\/r will depend on the programmatic characteristics. Alternatively, and if feasible, HIV drug resistance testing can be considered to guide the selection of first-line ART regimen (see Section 4.9 and Table 4.3).<\/p>\r\n\r\n<p>\u1d47 As of July 2021, the United States Food and Drug Administration and the European Medicines Agency have approved DTG for infants and children older than four weeks and weighing at least 3 kg.<\/p>\r\n\r\n<p><strong>Alternative regimen (adults and adolescents)<\/strong><\/p>\r\n\r\n<p>2. EFV at low dose (400 mg) in combination with an NRTI backbone is recommended as the alternative first-line regimen for adults and adolescents living with HIV initiating ART\u1d43 <em>(strong recommendation, moderate-certainty evidence).<\/em><\/p>\r\n\r\n<p>\u1d43 In settings in which pretreatment HIV drug resistance to NNRTIs is \u226510%, EFV-based ART should be avoided. EFV should also be avoided for people initiating or reinitiating first-line regimens with previous ARV drug exposure, regardless of the national prevalence of pretreatment drug resistance. See section 4.9 on HIV drug resistance considerations, Table 4.3 and Fig. 4.3.<\/p>\r\n\r\n<p><strong>Preferred regimen (neonates)<\/strong><\/p>\r\n\r\n<p>3. An RAL-based regimen may be recommended as the preferred first-line regimen for neonates <em>(conditional recommendation, very-low-certainty evidence).<\/em><\/p>\r\n","field_icon":null},{"field_title":"4.6.2 Second-line ART","field_content":"<p><strong>Non-DTG-based regimens<\/strong><\/p>\r\n\r\n<p>DTG in combination with an optimized nucleoside reverse-transcriptase inhibitor backbone may be recommended as a preferred second-line regimen for people living with HIV for whom non-DTG-based regimens are failing.<\/p>\r\n\r\n<ul>\r\n\t<li>Adults and adolescents <em>(conditional recommendation, moderate-certainty evidence)<\/em><\/li>\r\n\t<li>Children with approved DTG dosing <em>(conditional recommendation, low-certainty evidence)<\/em><\/li>\r\n<\/ul>\r\n\r\n<p><strong>DTG-based regimens<\/strong><\/p>\r\n\r\n<p>Boosted protease inhibitors in combination with an optimized nucleoside reverse-transcriptase inhibitor backbone are recommended as a preferred second-line regimen for people living with HIV for whom DTG-based regimens are failing <em>(strong recommendation, moderate-certainty evidence).<\/em><\/p>\r\n","field_icon":null},{"field_title":"4.6.3 Third-line ART","field_content":"<p>National programmes should develop policies for third-line ART <em>(conditional recommendation, low-certainty evidence).<\/em><\/p>\r\n\r\n<p>Third-line regimens should include new drugs with minimal risk of cross-resistance to previously used regimens, such as INSTIs and second-generation NNRTIs and PIs <em>(conditional recommendation, low-certainty evidence).<\/em><\/p>\r\n\r\n<p>People receiving a failing second-line regimen with no new ARV drug options should continue with a tolerated regimen <em>(conditional recommendation, very low-certainty evidence).<\/em><\/p>\r\n","field_icon":null}],"field_header":"4.6 What to start"},{"field_accordian":[{"field_title":" Monitoring the response to ART","field_content":"<p><strong>Preferred monitoring approach<\/strong><\/p>\r\n\r\n<p>Viral load is recommended as the preferred monitoring approach to diagnose and confirm treatment failure\u1d43<em>(strong recommendation, low-certainty evidence).<\/em><\/p>\r\n\r\n<p>\u1d43 Plasma specimens are preferred for viral load testing. Dried blood spot specimens are recommended in settings in which<\/p>\r\n\r\n<p>logistical, infrastructural or operational barriers prevent routine viral load monitoring using plasma specimens.<\/p>\r\n\r\n<p>Point-of-care viral load testing may be used to monitor treatment among people living with HIV receiving ART\u1d47 <em>(conditional recommendation, moderate-certainty evidence).<\/em><\/p>\r\n\r\n<p>\u1d47 See section 4.7 on using point-of-care viral load testing.<\/p>\r\n\r\n<p><strong>Timing of treatment monitoring<\/strong><\/p>\r\n\r\n<p>Routine viral load monitoring can be carried out by six months, at 12 months and then every 12 months thereafter if the person is established on ART to synchronize with routine monitoring and evaluation reporting <em>(conditional recommendation, very-low-certainty evidence).<\/em><\/p>\r\n\r\n<p>See Fig. 4.2 for an updated treatment monitoring algorithm.<\/p>\r\n\r\n<p><strong>Role of CD4 cell count monitoring<\/strong><\/p>\r\n\r\n<p>In settings in which routine viral load monitoring is available, CD4 cell count\u1d43 monitoring can be stopped for individuals who are established on ART\u1d47 <em>(conditional recommendation, low-certainty evidence).<\/em><\/p>\r\n\r\n<p>\u1d43 The timing and use of CD4 remains the same as in the 2016 WHO consolidated guidelines.<\/p>\r\n\r\n<p>\u1d47 Being established on ART includes suppressed viral loads (see section 7.3).<\/p>\r\n\r\n<p><strong>In settings where viral load is not routinely available<\/strong><\/p>\r\n\r\n<p>If viral load testing is not routinely available, CD4 count and clinical monitoring should be used to diagnose treatment failure <em>(strong recommendation, moderate-certainty evidence).<\/em><\/p>\r\n\r\n<p><strong>Use of dried blood spot specimens<\/strong><\/p>\r\n\r\n<p>Dried blood spot specimens using venous or capillary whole blood can be used to determine HIV viral load. A threshold of 1000 copies\/mL can be used to determine virological failure when using dried blood spot samples, as defined for testing in plasma\u1d43 <em>(conditional recommendation, low-certainty evidence).<\/em><\/p>\r\n\r\n<p>\u1d43 Plasma specimens are preferred for viral load testing. Dried blood spot specimens are recommended in settings in which logistical, infrastructural or operational barriers prevent routine viral load monitoring using plasma specimens.<\/p>\r\n","field_icon":null}],"field_header":"4.7 Monitoring the response to ART"},{"field_accordian":[{"field_title":"ARV drug resistance","field_content":"<p>For people initiating first-line ART with pretreatment HIV drug resistance to NNRTIs, a NNRTI-containing regimen should be avoided <em>(conditional recommendation, low-certainty evidence).<\/em><\/p>\r\n\r\n<p><strong>Consensus statement<\/strong><\/p>\r\n\r\n<p>In countries in which the prevalence of pretreatment HIV drug resistance to NNRTIs among people initiating first-line ART is equal to or greater than 10%, NNRTI-based ART should be avoided.<\/p>\r\n","field_icon":null}],"field_header":"4.9 ARV drug resistance"}],"field_content_type":{"tid":8,"name":"Accord","class":"accord"}}